56 related articles for article (PubMed ID: 23504336)
1. P38 MAPK expression and activation predicts failure of response to CHOP in patients with Diffuse Large B-Cell Lymphoma.
Vega GG; Avilés-Salas A; Chalapud JR; Martinez-Paniagua M; Pelayo R; Mayani H; Hernandez-Pando R; Martinez-Maza O; Huerta-Yepez S; Bonavida B; Vega MI
BMC Cancer; 2015 Oct; 15():722. PubMed ID: 26475474
[TBL] [Abstract][Full Text] [Related]
2. DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemoresistance.
Zhou N; Choi J; Grothusen G; Kim BJ; Ren D; Cao Z; Liu Y; Li Q; Inamdar A; Beer T; Tang HY; Perkey E; Maillard I; Bonasio R; Shi J; Ruella M; Wan L; Busino L
Blood; 2023 Sep; 142(11):973-988. PubMed ID: 37235754
[TBL] [Abstract][Full Text] [Related]
3. Advances in proteomics in diffuse large B‑cell lymphoma (Review).
Guo Z; Wang C; Shi X; Wang Z; Tao J; Ma J; Bi L
Oncol Rep; 2024 Jun; 51(6):. PubMed ID: 38757403
[TBL] [Abstract][Full Text] [Related]
4. Chemoresistance pathways in DLBCL.
Deaglio S
Blood; 2023 Sep; 142(11):943-944. PubMed ID: 37707876
[No Abstract] [Full Text] [Related]
5. Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas.
Rolland D; Basrur V; Conlon K; Wolfe T; Fermin D; Nesvizhskii AI; Lim MS; Elenitoba-Johnson KS
Am J Pathol; 2014 May; 184(5):1331-42. PubMed ID: 24667141
[TBL] [Abstract][Full Text] [Related]
6. Meta-Analysis of MS-Based Proteomics Studies Indicates Interferon Regulatory Factor 4 and Nucleobindin1 as Potential Prognostic and Drug Resistance Biomarkers in Diffuse Large B Cell Lymphoma.
Ejtehadifar M; Zahedi S; Gameiro P; Cabeçadas J; da Silva MG; Beck HC; Carvalho AS; Matthiesen R
Cells; 2023 Jan; 12(1):. PubMed ID: 36611989
[TBL] [Abstract][Full Text] [Related]
7. An integrated prognosis model of pharmacogenomic gene signature and clinical information for diffuse large B-cell lymphoma patients following CHOP-like chemotherapy.
Hu J; Xu J; Yu M; Gao Y; Liu R; Zhou H; Zhang W
J Transl Med; 2020 Mar; 18(1):144. PubMed ID: 32228625
[TBL] [Abstract][Full Text] [Related]
8. Multi-omics dataset to decipher the complexity of drug resistance in diffuse large B-cell lymphoma.
Fornecker LM; Muller L; Bertrand F; Paul N; Pichot A; Herbrecht R; Chenard MP; Mauvieux L; Vallat L; Bahram S; Cianférani S; Carapito R; Carapito C
Sci Rep; 2019 Jan; 9(1):895. PubMed ID: 30696890
[TBL] [Abstract][Full Text] [Related]
9. Determining protein biomarkers for DLBCL using FFPE tissues from HIV negative and HIV positive patients.
Magangane P; Sookhayi R; Govender D; Naidoo R
J Mol Histol; 2016 Dec; 47(6):565-577. PubMed ID: 27696080
[TBL] [Abstract][Full Text] [Related]
10. ALDH1A1 induces resistance to CHOP in diffuse large B-cell lymphoma through activation of the JAK2/STAT3 pathway.
Jiang J; Liu Y; Tang Y; Li L; Zeng R; Zeng S; Zhong M
Onco Targets Ther; 2016; 9():5349-60. PubMed ID: 27621650
[TBL] [Abstract][Full Text] [Related]
11. SILAC-Based Quantitative Proteomic Analysis of Diffuse Large B-Cell Lymphoma Patients.
Rüetschi U; Stenson M; Hasselblom S; Nilsson-Ehle H; Hansson U; Fagman H; Andersson PO
Int J Proteomics; 2015; 2015():841769. PubMed ID: 26060582
[TBL] [Abstract][Full Text] [Related]
12. Competing risks data analysis with high-dimensional covariates: an application in bladder cancer.
Tapak L; Saidijam M; Sadeghifar M; Poorolajal J; Mahjub H
Genomics Proteomics Bioinformatics; 2015 Jun; 13(3):169-76. PubMed ID: 25907251
[TBL] [Abstract][Full Text] [Related]
13. ALDH1A1 mediates resistance of diffuse large B cell lymphoma to the CHOP regimen.
Song YH; Zhong MZ; Gan PP; Yi PY; Tang YH; Liu YP; Jiang JQ; Li L
Tumour Biol; 2014 Dec; 35(12):11809-17. PubMed ID: 25344211
[TBL] [Abstract][Full Text] [Related]
14. Identification of differentially expressed proteins in chemotherapy-sensitive and chemotherapy-resistant diffuse large B cell lymphoma by proteomic methods.
Liu Y; Zeng L; Zhang S; Zeng S; Huang J; Tang Y; Zhong M
Med Oncol; 2013 Jun; 30(2):528. PubMed ID: 23504336
[TBL] [Abstract][Full Text] [Related]
15. 14-3-3zeta mediates resistance of diffuse large B cell lymphoma to an anthracycline-based chemotherapeutic regimen.
Maxwell SA; Li Z; Jaya D; Ballard S; Ferrell J; Fu H
J Biol Chem; 2009 Aug; 284(33):22379-22389. PubMed ID: 19525224
[TBL] [Abstract][Full Text] [Related]
16. Silencing Aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing β-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway.
Wang S; Sun L
Bioengineered; 2021 Dec; 12(1):8296-8308. PubMed ID: 34565287
[TBL] [Abstract][Full Text] [Related]
17. PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma.
Chen J; Ge X; Zhang W; Ding P; Du Y; Wang Q; Li L; Fang L; Sun Y; Zhang P; Zhou Y; Zhang L; Lv X; Li L; Zhang X; Zhang Q; Xue K; Gu H; Lei Q; Wong J; Hu W
Theranostics; 2020; 10(7):3151-3163. PubMed ID: 32194860
[TBL] [Abstract][Full Text] [Related]
18. Bcl-2 gene expression as a predictor of outcome in diffuse large B-cell lymphoma.
Shivakumar L; Armitage JO
Clin Lymphoma Myeloma; 2006 May; 6(6):455-7. PubMed ID: 16796775
[TBL] [Abstract][Full Text] [Related]
19. Treatment of aggressive non-Hodgkin's lymphoma: a north American perspective.
Sehn LH; Connors JM
Oncology (Williston Park); 2005 Apr; 19(4 Suppl 1):26-34. PubMed ID: 15934515
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
